Declaration of Bcr-Abl1 independence

Helong Zhao¹, Michael W Deininger^{2

3}

Affiliations

¹ Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
² Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA. Michael.Deininger@hci.utah.edu.
³ Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT, USA. Michael.Deininger@hci.utah.edu.

PMID: 32908250
DOI: 10.1038/s41375-020-01037-9

Review

Declaration of Bcr-Abl1 independence

Helong Zhao et al. Leukemia. 2020 Nov.

. 2020 Nov;34(11):2827-2836.

doi: 10.1038/s41375-020-01037-9. Epub 2020 Sep 10.

Authors

Helong Zhao¹, Michael W Deininger^{2

3}

Affiliations

¹ Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
² Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA. Michael.Deininger@hci.utah.edu.
³ Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT, USA. Michael.Deininger@hci.utah.edu.

PMID: 32908250
DOI: 10.1038/s41375-020-01037-9

No abstract available

PubMed Disclaimer

Cited by

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW. Osman AEG, et al. Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review.
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph⁺ leukemias?
Cruz-Rodriguez N, Tang H, Bateman B, Tang W, Deininger M. Cruz-Rodriguez N, et al. Leukemia. 2024 Sep;38(9):1885-1893. doi: 10.1038/s41375-024-02365-w. Epub 2024 Aug 4. Leukemia. 2024. PMID: 39098922 Free PMC article. Review.
Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review.
Lahmouad M, Rachid Z, Bellemrrabet R, Zerrouk J, Goh KW, Bouyahya A, Aboussalah Y. Lahmouad M, et al. Leuk Res Rep. 2025 Aug 5;24:100533. doi: 10.1016/j.lrr.2025.100533. eCollection 2025. Leuk Res Rep. 2025. PMID: 40823259 Free PMC article. Review.
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Alves R, et al. Cancers (Basel). 2021 Sep 26;13(19):4820. doi: 10.3390/cancers13194820. Cancers (Basel). 2021. PMID: 34638304 Free PMC article. Review.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Saussele S, Krauss M-P, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–9. - PubMed - PMC
1. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–61. - PubMed
1. Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. Br J Haematol. 2020;190:318–27. - PubMed - PMC
1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. - PubMed - PMC
1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Declaration of Bcr-Abl1 independence

Affiliations

Declaration of Bcr-Abl1 independence

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous